On September 25, 2018 CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody therapeutic technology platform, reported that members of its senior management team will participate at the following healthcare at conferences in October (Press release, CytomX Therapeutics, SEP 25, 2018, View Source [SID1234529609]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Third Annual FierceBiotech Drug Development Forum

Date: Tuesday, October 2, 2018
Location: Boston, Massachusetts

Sean McCarthy, D.Phil., chief executive officer, will participate in the panel discussion "Develop Combination Therapies for Immuno-Oncology"
Debanjan Ray, chief financial officer, will participate in the panel discussion "Update Collaboration Models Between Pharma and Biotech"
Cantor Fitzgerald Global Healthcare Conference

Date: Wednesday, October 3, 2018
Time: 1:05pm EDT
Location: New York, New York

A live audio webcast of the Cantor presentation will be available through the Investors and News section of CytomX’s website. An archived replay will be available for 90 days following the event.